Notably, vorasidenib received approval from the United States Food and Drug Administration (FDA) in August 2024 for the treatment of grade 2 oligodendroglioma and grade 2 IDH-mutant astrocytoma (2). This evidence concerns the gene IDH2 and astrocytoma (excluding glioblastoma).